AlphaYou
Overview
Smart money at a glance
Filings to Oct 1, 2026Net selling: insiders sold $33.1M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$33.1M netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 0 added, 2 cutMore cutting
Key stats
Fundamentals Sep 30- Open
- $143.45
- 52-wk high
- $160.81
- High
- $144.09
- 52-wk low
- $62.24
- Low
- $138.88
- Prev close
- $142.44
- Mkt cap
- $9.22B
- P/E
- 137.0x
- Volume
- 508.0K
- Fwd P/E
- 36.9x
- Beta
- 1.79
- P/S
- 32.7x
- P/B
- 10.7x
- Profit margin
- +29.4%
- Op margin
- +74.4%
- ROE
- +11.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about PTGX filings
Are insiders buying or selling Protagonist Therapeutics Inc (PTGX) stock?
Net selling: insiders sold $33.1M and bought $0 of PTGX stock on the open market in the 90 days to Oct 1, 2026, according to SEC Form 4 filings. $33.1M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Patel, Dinesh V Ph D (President and CEO), who sold $33.1M. The latest filing was on Sep 11, 2026.
Which members of Congress have traded PTGX recently?
None. No member of Congress disclosed a PTGX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this PTGX smart-money data?
This summary uses filings available on Oct 1, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Sells/Trims (2)
- CI
Citadel
$163.6M
sold
- MW
Marshall Wace
$52.8M
trimmed
What insiders are doing
Sells (3)
- PD
Patel Dinesh V Ph D
$18.2M
sold
- PD
Patel Dinesh V Ph D
$14.9M
sold
- WW
Waddill William D.
$1.1M
sold
How top traders are positioned
No tracked top-trader positions in PTGX right now.
Live Hyperliquid positioning - not every stock is covered
Activist stakes, short interest & more
Earnings
Earnings came in 8.5% above what analysts expected.
Earnings per share
$2.11 expected
Reports Nov 5, 2026, in 35 days
Estimates as of Sep 29, 2026
EPS expected
$0.13 to $3.71
Revenue expected
11 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $4.7M | $7.4M | $56.4M | $213.5M |
| Cost of what it sold | — | $376.0K | $407.0K | — |
| Gross profit | $4.7M | $7.4M | $56.0M | $213.5M |
| What it spent | ||||
| Research and development | $40.0M | $46.4M | $46.7M | $42.1M |
| Sales and admin | $11.1M | $11.4M | $13.3M | $12.6M |
| Total operating expenses | $51.1M | $57.8M | $59.6M | $54.7M |
| What was left | ||||
| Operating profit | -$46.4M | -$50.4M | -$3.6M | $158.8M |
| Profit before tax | -$39.3M | -$43.7M | $2.3M | $165.1M |
| Tax | — | $666.0K | -$1.5M | $2.3M |
| Net profit | -$39.3M | -$44.4M | $3.8M | $162.8M |
| EBITDA | -$39.0M | -$43.3M | $2.7M | $165.1M |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
BullishSep 26Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up - What's Next?
BullishSep 25Protagonist Therapeutics (PTGX) Short Interest & Short Float | Updated Sep 2026
Leans bearishSep 25Protagonist Therapeutics, Inc. (PTGX) Stock forecasts
BullishSep 24Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Exploring a 20% Potential Upside with Robust Revenue Growth
BullishSep 221,324,498 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Bank of America Corp DE
BullishSep 18
Macro
11 macro signals shaping PTGX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results